New Enterprise Associates

ZeroFOX is a cybersecurity company that provides external threat intelligence and protection against social media–based threats. It operates a cloud-based platform delivering real-time social threat analytics, protection, and monitoring to safeguard brands, people, and data across the public attack surface. Its solutions address phishing, credential compromise, impersonation, information leakage, brand hijacking, and physical or reputational risks to executives and high-profile individuals, with services including managed monitoring and protection. The company supports industries such as financial services, retail, government, healthcare, technology, education, media, and sports, and offers specialized protections for elections and high-value personnel.

IonQ is a quantum computing company that develops general-purpose quantum information processors based on trapped-ion technology. Its approach enables qubit replication, optical networkability, and optimized algorithms to support scalable quantum computation beyond classical capabilities. Founded in 2015 and based in College Park, Maryland, IonQ offers access to its quantum computers through cloud platforms, providing quantum-computing-as-a-service to a broad user base and select customers through its own cloud service. Revenue streams include QCaaS arrangements and related consulting and co-development contracts for algorithm design and system integration.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

ZeroFOX is a cybersecurity company that provides external threat intelligence and protection against social media–based threats. It operates a cloud-based platform delivering real-time social threat analytics, protection, and monitoring to safeguard brands, people, and data across the public attack surface. Its solutions address phishing, credential compromise, impersonation, information leakage, brand hijacking, and physical or reputational risks to executives and high-profile individuals, with services including managed monitoring and protection. The company supports industries such as financial services, retail, government, healthcare, technology, education, media, and sports, and offers specialized protections for elections and high-value personnel.

IonQ is a quantum computing company that develops general-purpose quantum information processors based on trapped-ion technology. Its approach enables qubit replication, optical networkability, and optimized algorithms to support scalable quantum computation beyond classical capabilities. Founded in 2015 and based in College Park, Maryland, IonQ offers access to its quantum computers through cloud platforms, providing quantum-computing-as-a-service to a broad user base and select customers through its own cloud service. Revenue streams include QCaaS arrangements and related consulting and co-development contracts for algorithm design and system integration.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

IonQ is a quantum computing company that develops general-purpose quantum information processors based on trapped-ion technology. Its approach enables qubit replication, optical networkability, and optimized algorithms to support scalable quantum computation beyond classical capabilities. Founded in 2015 and based in College Park, Maryland, IonQ offers access to its quantum computers through cloud platforms, providing quantum-computing-as-a-service to a broad user base and select customers through its own cloud service. Revenue streams include QCaaS arrangements and related consulting and co-development contracts for algorithm design and system integration.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

Blispay Inc. is a financial technology company based in Baltimore, Maryland, founded in 2014. It develops a mobile application designed for online bill payments and provides a unique financing solution for retailers through its Blispay Visa Card. This mobile-centric credit card allows merchants, regardless of size, to offer a streamlined in-store financing experience without the need for technical integration or financial commitments. Customers benefit from instant card issuance, six months of special financing options, and 2% cash back on purchases. Blispay aims to enhance the shopping experience by providing everyday credit and financing solutions that cater to the needs of both consumers and small to midsize retailers, ultimately helping businesses increase sales and improve customer satisfaction. The founding team comprises seasoned professionals with backgrounds at notable companies including PayPal and Microsoft.

Vtesse, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, focused on developing treatments for patients with rare diseases. The company is primarily engaged in the clinical study of VTS-270 for the treatment of Niemann-Pick Disease Type C (NPC) and is also involved in the pre-clinical discovery and development of additional novel drugs for NPC and other lysosomal storage diseases. Vtesse operates as a subsidiary of Sucampo Pharmaceuticals, Inc. and is recognized as the first spin-out from Cydan Development, Inc., an orphan-drug accelerator. The company collaborates with the National Institutes of Health (NIH) to advance its clinical programs and is supported by a seasoned management team with extensive experience in drug development. Vtesse's initiatives aim not only to provide innovative therapies but also to offer resources and support for patients and families affected by NPC and related conditions.

Blispay Inc. is a financial technology company based in Baltimore, Maryland, founded in 2014. It develops a mobile application designed for online bill payments and provides a unique financing solution for retailers through its Blispay Visa Card. This mobile-centric credit card allows merchants, regardless of size, to offer a streamlined in-store financing experience without the need for technical integration or financial commitments. Customers benefit from instant card issuance, six months of special financing options, and 2% cash back on purchases. Blispay aims to enhance the shopping experience by providing everyday credit and financing solutions that cater to the needs of both consumers and small to midsize retailers, ultimately helping businesses increase sales and improve customer satisfaction. The founding team comprises seasoned professionals with backgrounds at notable companies including PayPal and Microsoft.

ZeroFOX is a cybersecurity company that provides external threat intelligence and protection against social media–based threats. It operates a cloud-based platform delivering real-time social threat analytics, protection, and monitoring to safeguard brands, people, and data across the public attack surface. Its solutions address phishing, credential compromise, impersonation, information leakage, brand hijacking, and physical or reputational risks to executives and high-profile individuals, with services including managed monitoring and protection. The company supports industries such as financial services, retail, government, healthcare, technology, education, media, and sports, and offers specialized protections for elections and high-value personnel.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Vtesse, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, focused on developing treatments for patients with rare diseases. The company is primarily engaged in the clinical study of VTS-270 for the treatment of Niemann-Pick Disease Type C (NPC) and is also involved in the pre-clinical discovery and development of additional novel drugs for NPC and other lysosomal storage diseases. Vtesse operates as a subsidiary of Sucampo Pharmaceuticals, Inc. and is recognized as the first spin-out from Cydan Development, Inc., an orphan-drug accelerator. The company collaborates with the National Institutes of Health (NIH) to advance its clinical programs and is supported by a seasoned management team with extensive experience in drug development. Vtesse's initiatives aim not only to provide innovative therapies but also to offer resources and support for patients and families affected by NPC and related conditions.

D2L is a global provider of cloud-based learning solutions for higher education, K-12, healthcare, government, and enterprise. It offers Brightspace, a scalable learning platform with integrated analytics and accessibility features, together with a suite of tools for adaptive learning, content management, assessment, ePortfolios, course catalogs, and campus engagement. The company serves hundreds of clients, including Fortune 1000 organizations, and supports more than eight million learners worldwide. Founded in 1999 and headquartered in Kitchener, Canada, D2L operates with offices and teams across North America, Europe, and Australia to deliver accessible, engaging, and personalized learning experiences.

Cerecor Inc. is a biopharmaceutical company dedicated to the development and commercialization of treatments for rare pediatric and orphan diseases. Founded in 2011 and headquartered in Rockville, Maryland, the company is advancing a clinical-stage pipeline that includes therapies for inherited metabolic disorders, such as CERC-801, CERC-802, and CERC-803, which are focused on congenital disorders of glycosylation. Additionally, Cerecor is developing CERC-006, an oral mTOR inhibitor aimed at treating complex lymphatic malformations, and two monoclonal antibodies: CERC-002, targeting the cytokine LIGHT for severe pediatric-onset Crohn's disease, and CERC-007, targeting IL-18 for autoimmune inflammatory diseases like adult onset Still's disease and multiple myeloma. Several of these therapies have received Orphan Drug Designation and Rare Pediatric Disease Designation, qualifying them for expedited review upon FDA approval. Cerecor also offers Millipred, an oral prednisolone for various inflammatory conditions.

NexImmune, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focused on developing innovative immuno-therapeutics utilizing its proprietary Artificial Immune (AIM) technology. Founded in 2011, the company aims to enhance the immune system's response to various diseases, including cancer, inflammation, viral infections, transplant rejection, and autoimmunity. NexImmune's lead product candidates are AIM101, an aAPC-based injectable therapy targeting specific solid tumors, and AIM ACT, an adoptive cellular therapy for hematological malignancies. The AIM technology facilitates a controllable and reproducible immune response by leveraging the body's T cells to initiate targeted actions against specific antigens, even in conditions where natural antigen presenting cells are compromised. Currently, NexImmune is advancing its therapies through clinical trials, including NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

ZeroFOX is a cybersecurity company that provides external threat intelligence and protection against social media–based threats. It operates a cloud-based platform delivering real-time social threat analytics, protection, and monitoring to safeguard brands, people, and data across the public attack surface. Its solutions address phishing, credential compromise, impersonation, information leakage, brand hijacking, and physical or reputational risks to executives and high-profile individuals, with services including managed monitoring and protection. The company supports industries such as financial services, retail, government, healthcare, technology, education, media, and sports, and offers specialized protections for elections and high-value personnel.

Bravo Health, Inc. is a managed care organization that specializes in providing Medicare Advantage options, catering specifically to Medicare beneficiaries, including those who are dually eligible for Medicare and Medicaid. The company offers a range of plans, including special needs plans for individuals receiving institutional care or those with chronic health conditions, as well as private fee-for-service plans that allow members to choose their healthcare providers. Additionally, Bravo Health provides Part D prescription drug plans to cover medication needs. The company operates in multiple states, including Delaware, Maryland, Pennsylvania, Texas, and Washington, and has expanded its services to offer prescription drug coverage in 43 states. Founded in 1996 and headquartered in Baltimore, Maryland, Bravo Health was previously known as Elder Health, Inc.

D2L is a global provider of cloud-based learning solutions for higher education, K-12, healthcare, government, and enterprise. It offers Brightspace, a scalable learning platform with integrated analytics and accessibility features, together with a suite of tools for adaptive learning, content management, assessment, ePortfolios, course catalogs, and campus engagement. The company serves hundreds of clients, including Fortune 1000 organizations, and supports more than eight million learners worldwide. Founded in 1999 and headquartered in Kitchener, Canada, D2L operates with offices and teams across North America, Europe, and Australia to deliver accessible, engaging, and personalized learning experiences.

Sonatype, Inc. is a provider of software supply chain automation solutions, established in 2008 and headquartered in Fulton, Maryland, with additional offices in McLean, Virginia; London, United Kingdom; and Sydney, Australia. The company offers a comprehensive suite of tools designed to manage and secure software supply chains, including Nexus Lifecycle, Nexus Firewall, Nexus Auditor, Nexus Repository, and Nexus Repository OSS. These solutions help organizations control the flow of components, prevent risky elements from entering the supply chain, monitor applications in production, and efficiently store and distribute software components. Serving a diverse range of industries such as finance, government, technology, insurance, healthcare, and manufacturing, Sonatype supports approximately 70% of the Fortune 100 and is utilized by over 15 million developers globally. Recognized for its innovative workplace culture and growth, Sonatype continues to transform cloud-native development lifecycles, ensuring higher quality, maintainable, and secure software.

Millennial Media Inc. is a prominent provider of mobile advertising solutions, catering to advertisers and developers in the United States and internationally. Founded in 2006 and headquartered in Baltimore, Maryland, the company offers a range of services that enable advertisers to effectively reach and engage their target audiences across various mobile devices. Its offerings include a demand-side platform for direct inventory access, a premium mobile advertising exchange, and tools for designing advertisements. Millennial Media also supports developers with software development kits for various ad formats, ad serving capabilities, and mediation tools that optimize ad requests from multiple sources. Additionally, the company operates MYDAS, a mobile advertising technology that identifies unique users and tailors ad delivery based on interests and behaviors. Millennial Media serves a significant portion of leading advertisers and is recognized for providing an attractive monetization platform for app developers and publishers.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Millennial Media Inc. is a prominent provider of mobile advertising solutions, catering to advertisers and developers in the United States and internationally. Founded in 2006 and headquartered in Baltimore, Maryland, the company offers a range of services that enable advertisers to effectively reach and engage their target audiences across various mobile devices. Its offerings include a demand-side platform for direct inventory access, a premium mobile advertising exchange, and tools for designing advertisements. Millennial Media also supports developers with software development kits for various ad formats, ad serving capabilities, and mediation tools that optimize ad requests from multiple sources. Additionally, the company operates MYDAS, a mobile advertising technology that identifies unique users and tailors ad delivery based on interests and behaviors. Millennial Media serves a significant portion of leading advertisers and is recognized for providing an attractive monetization platform for app developers and publishers.

Optinuity, Inc. specializes in autonomic policy management solutions designed for enterprises and service providers. Founded in 2004 and headquartered in Bethesda, Maryland, the company focuses on helping organizations streamline complex business systems through self-management capabilities. One of its key offerings is Optinuity Oasis, a software solution that facilitates the creation and implementation of autonomic policies. In addition to software solutions, Optinuity provides a range of professional services, including policy planning and design, installation and configuration, custom development, and training. Its services are primarily targeted at sectors such as financial services, health care, and telecommunications. As of October 2008, Optinuity operates as a subsidiary of CA, Inc.

Hillcrest Laboratories is a prominent global supplier of motion processing solutions, specializing in the use of MEMS sensors to capture and translate human and mechanical movements into actionable motion patterns. This technology is utilized across various sectors, including consumer electronics and industrial applications. Known for its significant contributions to the Smart TV industry, Hillcrest Labs developed HoME, the first pointer-based interactive media system for television, along with the award-winning Loop remote control. The company has expanded its reach to the smartphone and mobile device markets, licensing technology for leading gaming systems and providing solutions for virtual reality applications. Hillcrest Labs has garnered numerous accolades, including multiple CES Innovations Awards and recognition from notable publications such as PC World and Popular Mechanics. Founded in 2001 by Dan Simpkins and based in Rockville, Maryland, Hillcrest Labs continues to innovate in sensor processing and data fusion, offering advanced 9-axis and 6-axis embedded systems and software for applications in robotics, augmented reality, and handheld motion control.

Optinuity, Inc. specializes in autonomic policy management solutions designed for enterprises and service providers. Founded in 2004 and headquartered in Bethesda, Maryland, the company focuses on helping organizations streamline complex business systems through self-management capabilities. One of its key offerings is Optinuity Oasis, a software solution that facilitates the creation and implementation of autonomic policies. In addition to software solutions, Optinuity provides a range of professional services, including policy planning and design, installation and configuration, custom development, and training. Its services are primarily targeted at sectors such as financial services, health care, and telecommunications. As of October 2008, Optinuity operates as a subsidiary of CA, Inc.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Sourcefire, Inc. is a provider of enterprise threat management solutions focused on enhancing the cybersecurity of IT infrastructures across various sectors, including healthcare, financial services, manufacturing, energy, education, retail, telecommunications, and government organizations. Founded in 2001 and headquartered in Columbia, Maryland, the company develops both open source and commercial security products. Notably, its offerings include Snort, an open source intrusion prevention technology, and the Sourcefire 3D System, which integrates multiple security solutions such as intrusion prevention, network behavior analysis, and vulnerability assessment within a unified management framework. Additionally, Sourcefire provides ClamAV, an open source anti-virus and anti-malware solution. Alongside its products, the company offers technical support and professional services that encompass network security deployment, customer support, and certification training. Sourcefire markets its products through a direct sales force and through partnerships with resellers, distributors, and original equipment manufacturers.

Optinuity, Inc. specializes in autonomic policy management solutions designed for enterprises and service providers. Founded in 2004 and headquartered in Bethesda, Maryland, the company focuses on helping organizations streamline complex business systems through self-management capabilities. One of its key offerings is Optinuity Oasis, a software solution that facilitates the creation and implementation of autonomic policies. In addition to software solutions, Optinuity provides a range of professional services, including policy planning and design, installation and configuration, custom development, and training. Its services are primarily targeted at sectors such as financial services, health care, and telecommunications. As of October 2008, Optinuity operates as a subsidiary of CA, Inc.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Psyadon Pharmaceuticals is a biopharmaceutical company based in Germantown, Maryland, focused on discovering and developing new treatments for serious psychiatric and neurological diseases. Founded in 2004, the company has been dedicated to creating innovative solutions for conditions that often lack effective therapies. One of its key developments is Ecopipam, a drug designed to selectively block the actions of the neurotransmitter dopamine at the D1 subtype in the brain. Psyadon Pharmaceuticals was formerly known as Ruxton Pharmaceuticals and changed its name in October 2008. As of August 14, 2018, it operates as a subsidiary of Emalex Biosciences.

Sourcefire, Inc. is a provider of enterprise threat management solutions focused on enhancing the cybersecurity of IT infrastructures across various sectors, including healthcare, financial services, manufacturing, energy, education, retail, telecommunications, and government organizations. Founded in 2001 and headquartered in Columbia, Maryland, the company develops both open source and commercial security products. Notably, its offerings include Snort, an open source intrusion prevention technology, and the Sourcefire 3D System, which integrates multiple security solutions such as intrusion prevention, network behavior analysis, and vulnerability assessment within a unified management framework. Additionally, Sourcefire provides ClamAV, an open source anti-virus and anti-malware solution. Alongside its products, the company offers technical support and professional services that encompass network security deployment, customer support, and certification training. Sourcefire markets its products through a direct sales force and through partnerships with resellers, distributors, and original equipment manufacturers.

Hillcrest Laboratories is a prominent global supplier of motion processing solutions, specializing in the use of MEMS sensors to capture and translate human and mechanical movements into actionable motion patterns. This technology is utilized across various sectors, including consumer electronics and industrial applications. Known for its significant contributions to the Smart TV industry, Hillcrest Labs developed HoME, the first pointer-based interactive media system for television, along with the award-winning Loop remote control. The company has expanded its reach to the smartphone and mobile device markets, licensing technology for leading gaming systems and providing solutions for virtual reality applications. Hillcrest Labs has garnered numerous accolades, including multiple CES Innovations Awards and recognition from notable publications such as PC World and Popular Mechanics. Founded in 2001 by Dan Simpkins and based in Rockville, Maryland, Hillcrest Labs continues to innovate in sensor processing and data fusion, offering advanced 9-axis and 6-axis embedded systems and software for applications in robotics, augmented reality, and handheld motion control.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Iomai Corporation, established in 1997 and headquartered in Gaithersburg, Maryland, specializes in the discovery and development of vaccines and immune system stimulants. The company's unique approach involves a needle-free delivery method known as transcutaneous immunization (TCI), which harnesses the skin's antigen-presenting cells to generate an enhanced immune response. Iomai leverages this technology to improve existing vaccines, enable new ones, and expand global vaccine accessibility. Following its acquisition by Intercell AG in 2008, Iomai operates as a subsidiary under the name Intercell USA Inc.